The most recent issue of
Pharmaceutical Technology Europe, they profile the landscape of biosimilars. In this issue they cover
The Biosimilars Market of Today and Tomorrow, A SWOT analysis of the biosimilars market, Latest EU Guidelines, Launching and Commercializing Biosimilars and more. To discuss any of these articles in depth,
join our Business of Biosimilars LinkedIn group where over 300 professionals around the world discussing the latest news and information in biosimilars.
|
Share this article with your social network, just click below to share now!
|
|
|
The global synthetic biology market is supposed to reach $13.4 billion by 2019. A recent study from Transparency Market Research shows that...
Oren Levy from Karp Lab gave an excellent talk called “MSCs on Steriods” last month at Biotech Week Boston. Oren's research focus is &q...
If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, an...
1 comment :
Though biosimilars are highly valued for their effectiveness as treatments, the costs-per-patient of many biologics are often significant and sometimes can be prohibitive. As all countries tussle with the issues of access to biologics and other medicines while confronting increasingly limited health care resources; achievement of the full potential of biosimilars is becoming increasingly challanging. My collegues and I recently authored one of the most indepth reports on the Biosimilars industry in India. If anyone is interested in this, feel free to write to me at infoalcpl@gmail.com. Ashritha.
Post a Comment